janus kinase (JAK) inhibitor - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID-19 mild to moderate

	COVID-19 mild to moderate
janus kinase (JAK) inhibitor
baricitinib	Rodriguez-Garcia Cantini
tofacitinib	Murugesan

1 studies excluded by filtering options 2

6415

Cantini, 2020

2

31

0

excluded

not a RCT

risk of bias not avaialble